---
input_text: 'Seizure management and prescription patterns of anticonvulsants in Dravet
  syndrome: A multicenter cohort study from Germany and review of literature. OBJECTIVE:
  The aim of this study was to describe the treatment pattern of patients with Dravet
  syndrome (DS) in Germany with routine antiepileptic drugs (AEDs) and emergency medication,
  and to review the literature of real-world evidence on medicine utilization of patients
  with DS in Europe. METHODS: Patient use of routine AEDs and emergency medications
  over 3-6 months was analyzed from a 2018 multicenter survey of 93 caregivers of
  patients with DS throughout Germany. Results were contextualized in a review of
  real-world evidence on medicine utilization of patients with DS in Europe. RESULTS:
  The variety of medications and the most frequent combinations routinely used by
  patients with DS (AEDs and others) are described. Patients use a large number of
  pharmaceutical treatments to manage seizures. The five most commonly used AEDs were
  sodium valproate (66% of the patients; mean daily dose: 660 mg; 24.5 mg per kg bodyweight),
  bromide (44%; 1462 mg; 51.2 mg per kg), clobazam (41%; 10.4 mg; 0.32 mg per kg),
  stiripentol (35%; 797 mg; 27.6 mg per kg), and topiramate (24%; 107 mg; 3.5 mg per
  kg). Ninety percent had reported using emergency medications in the last 3 months;,
  with the most common medications being Buccolam (40%, an oromucosal form of midazolam)
  and diazepam (20%, mostly rectal application). No discernable relationships between
  current medication and age or seizure frequency were observed. SIGNIFICANCE: This
  is the first comprehensive report of routine AEDs and emergency medication use in
  a large sample of patients with DS in Germany over a period of 3-6 months and shows
  that despite the most common AED combinations being in line with clinical guidelines/best
  practice, there is no discernable impact of best treatment on seizure frequency.
  We find a higher use of bromide in Germany compared with other real-world evidence
  in Europe.'
raw_completion_output: |-
  primary_disease: Dravet syndrome

  medical_actions: prescription of anticonvulsants; emergency medication use; routine use of AEDs; review of real-world evidence on medicine utilization

  symptoms: seizures

  chemicals: sodium valproate; bromide; clobazam; stiripentol; topiramate; Buccolam (midazolam); diazepam

  action_annotation_relationships: prescription of anticonvulsants TREATS seizures IN Dravet syndrome; emergency medication use TREATS seizures IN Dravet syndrome; routine use of AEDs TREATS seizures IN Dravet syndrome; sodium valproate TREATS seizures IN Dravet syndrome; bromide TREATS seizures IN Dravet syndrome; clobazam TREATS seizures IN Dravet syndrome; stiripentol TREATS seizures IN Dravet syndrome; topiramate TREATS seizures IN Dravet syndrome; Buccolam (midazolam) TREATS seizures IN Dravet syndrome; diazepam TREATS seizures IN Dravet syndrome
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  diazepam TREATS seizures IN Dravet syndrome

  ===

extracted_object:
  primary_disease: MONDO:0100135
  medical_actions:
    - prescription of anticonvulsants
    - emergency medication use
    - routine use of AEDs
    - review of real-world evidence on medicine utilization
  symptoms:
    - HP:0001250
  chemicals:
    - CHEBI:9925
    - CHEBI:15858
    - CHEBI:31413
    - CHEBI:228488
    - CHEBI:63631
    - CHEBI:6931
    - CHEBI:49575
  action_annotation_relationships:
    - subject: prescription of anticonvulsants
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:35623
    - subject: emergency medication use
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
    - subject: routine use of AEDs
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_qualifier: routine
      subject_extension: CHEBI:40594
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:9925
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:15858
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:31413
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:228488
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:63631
    - subject: Buccolam
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:6931
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:49575
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
  - id: HP:0012758
    label: Neurodevelopmental delays
  - id: HP:0011951
    label: Aspiration pneumonia
  - id: CHEBI:71013
    label: Perampanel
  - id: CHEBI:63004
    label: Sodium bromide
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0000718
    label: Aggression
  - id: HP:0031475
    label: nonconvulsive status epilepticus
  - id: HP:0001609
    label: hoarseness
  - id: HP:0000752
    label: hyperactivity
  - id: HP:0002446
    label: astrogliosis
  - id: CHEBI:9948
    label: verapamil
  - id: CHEBI:52140
    label: clemizole
  - id: CHEBI:3387
    label: Carbamazepine
  - id: CHEBI:40594
    label: AEDs
